Kenvue stock (US49177J1025): Q1 growth accelerates ahead of Kimberly-Clark deal

Kenvue reported Q1 2026 net sales growth of 4.5% with Skin Health and Beauty surging 8.4%, signaling strong momentum as the consumer health company advances toward its planned acquisition by Kimberly-Clark.

Kenvue, the consumer health company spun off from Johnson & Johnson in 2023, delivered robust first-quarter 2026 results, with net sales climbing 4.5% year-over-year to the fiscal quarter ending March 29, 2026, according to Personal Care Insights as of May 2026. The company's Skin Health and Beauty segment emerged as the strongest performer, recording net sales growth of 8.4% with organic sales increasing 5%, driven by innovation and e-commerce expansion across flagship brands including Neutrogena and OGX.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kenvue Inc.
• Sector/industry: Consumer Staples / Household Products
• Headquarters/country: Skillman, New Jersey, United States
• Core markets: United States and global consumer health
• Key revenue drivers: Skin and beauty care (Neutrogena, Aveeno), baby care (Johnson's), oral care (Listerine), OTC medicines (Tylenol, Motrin)
• Home exchange/listing venue: NYSE (KVUE)
• Trading currency: USD

Kenvue: core business model

Kenvue operates as a pure-play consumer health company focused on self-care brands spanning skin health, beauty, essential health, and pain relief. Formed via corporate separation from Johnson & Johnson in May 2023, the company raised $3.3 billion in its initial public offering at $20–$23 per share, according to MarketBeat as of May 2026. The company targets everyday consumer needs through a portfolio of trusted, science-backed brands with over a century of heritage.

Main revenue and product drivers for Kenvue

Kenvue's revenue streams span multiple consumer health categories. Skin and beauty care, anchored by Neutrogena and Aveeno, generated the strongest Q1 growth at 8.4% net sales increase. Baby care products under the Johnson's brand, oral care via Listerine, and over-the-counter pharmaceuticals including Tylenol and Motrin round out the portfolio. Organic sales rose 0.7% in Q1 2026, while the Self Care segment reported net sales growth of 1.9%, though organic sales in that division declined 2.3% due to weaker cold and flu seasons in major markets.

The stock traded at $17.20 USD on May 12, 2026, on the New York Stock Exchange, down 2.19% for the session, according to MarketBeat as of May 12, 2026. The company carries a consensus analyst rating of Hold with a price target of $19.33 and a dividend yield of 4.82%.

Why Kenvue matters for US investors

Kenvue represents a significant pure-play exposure to the consumer health and over-the-counter pharmaceutical market, a sector with steady demand and recurring revenue characteristics. As a New York Stock Exchange-listed company with a 4.82% dividend yield, Kenvue appeals to income-focused investors seeking exposure to essential consumer staples. The company's planned acquisition by Kimberly-Clark, a major multinational consumer goods manufacturer, adds a potential catalyst for shareholders and underscores the strategic value of Kenvue's brand portfolio in the broader consumer health landscape.

Operational momentum and margin improvement

Beyond top-line growth, Kenvue demonstrated operational efficiency gains in Q1 2026, with improved margins and earnings supporting the company's financial trajectory. The combination of organic sales growth in the high-performing Skin Health and Beauty segment, coupled with e-commerce expansion and innovation initiatives, suggests the company is successfully executing its growth strategy despite headwinds in seasonal categories. These operational improvements provide a foundation for sustained profitability as the company navigates the transition toward its acquisition by Kimberly-Clark.

Conclusion

Kenvue's Q1 2026 results demonstrate solid execution across its consumer health portfolio, with double-digit growth in its highest-margin Skin Health and Beauty segment offsetting seasonal weakness in cold and flu remedies. The company's 4.5% net sales growth, combined with margin expansion and a 4.82% dividend yield, positions it as a stable income-generating play in the consumer staples sector for US investors. As the planned Kimberly-Clark acquisition progresses, shareholders will monitor regulatory developments and integration timelines, while the company's strong brand portfolio and operational improvements suggest resilience in an evolving consumer health market.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.